An Avandia lawsuit filed by Louisiana Attorney General Buddy Caldwell claims that diabetes drug maker GlaxoSmithKline wrongfully and illegally marketed, priced, sold and promoted the diabetes drug rosiglitazone maleate under the trade names Avandia®, Avandamet®, and Avandaryl®, violating Louisiana’s Medical Assistance Programs Integrity Law (MAPIL), the Unfair Trade Practices and Consumer Protections Law and other LA state laws.
Attorney General Caldwell issued the following statement about the Avandia lawsuit:
“I am committed to pursuing those who prey on our citizens and our state Medicaid program. This type of exploitation jeopardizes our economy, our health and in some cases our lives. Our focus on these perpetrators sends a message of zero tolerance for such fraud and abuse.”
The LA Attorney General’s office is working closely with the Department of Health and Hospitals on the case. DHH Secretary Bruce D. Greenstein also issued a statement:
“I welcome Attorney General Caldwell’s tough stance in helping us protect precious Medicaid dollars. It is terribly disturbing that a company this size would take advantage of people by offering misleading information and take funds away from those who need it most. We are committed to rooting out abuse and misuse of Medicaid money wherever it occurs and to working with the Attorney General to ensure accountability for those who prey on the system.”
The lawsuit seeks to recover compensation for the more than $36 million in Avandia reimbursements paid by the Louisiana Medicaid program to GlaxoSmithKline. The lawsuit claims that GSK fraudulently induced the Avandia reimbursements. The case is civil action for civil fines, civil penalties, restitution and other monetary relief.
The attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases.